Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of once-weekly MET097 in adults with obesity or overweight and Type 2 Diabetes Mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• MET097

Snippet

Sponsor: Metsera, a wholly owned subsidiary of Pfizer | Conditions: Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Status: COMPLETED